Literature DB >> 20202599

Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus.

Cynthia Aranow1, Betty Diamond, Meggan Mackay.   

Abstract

The recent appreciation that a subset of anti-DNA antibodies cross-reacts with the N-methyl-d-aspartate receptor encourages a renewed examination of antibrain reactivity in systemic lupus erythematosus (SLE) autoantibodies. Moreover, investigations of their autospecificity present a paradigm for studies of antibrain reactivity and show that (1) serum antibodies access brain tissue only after a compromise of blood-brain barrier integrity, (2) the same antibodies have differential effects on brain function depending on the region of brain exposed to the antibodies, and (3) insults to the blood-brain barrier are regional rather than diffuse. These studies suggest that an anatomic classification scheme for neuropsychiatric SLE may facilitate research on etiopathogenesis and the design of clinical trials. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202599      PMCID: PMC2837540          DOI: 10.1016/j.rdc.2009.12.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  79 in total

1.  Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep.

Authors:  Robin L Brey; Michelle A Petri
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

2.  Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens.

Authors:  A Sharma; D Isenberg; B Diamond
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

3.  Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine.

Authors:  J W Olney; O L Ho
Journal:  Nature       Date:  1970-08-08       Impact factor: 49.962

4.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

5.  Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies.

Authors:  Giovanni Sanna; Maria L Bertolaccini; Maria J Cuadrado; Hana Laing; Munther A Khamashta; Alessandro Mathieu; Graham R V Hughes
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

6.  Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.

Authors:  Estelle Trysberg; Karin Nylen; Lars E Rosengren; Andrej Tarkowski
Journal:  Arthritis Rheum       Date:  2003-10

7.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; John R Brandt; Courtney R Johnson; Marcos E Maldonado; Samir R Patel; Corey C Ford; Arthur D Bankhurst; William M Brooks
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

8.  Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children.

Authors:  Gail Ross; Lisa Sammaritano; Ruth Nass; Michael Lockshin
Journal:  Arch Pediatr Adolesc Med       Date:  2003-04

9.  Cognition and immunity; antibody impairs memory.

Authors:  Czeslawa Kowal; Lorraine A DeGiorgio; Tsukasa Nakaoka; Hoby Hetherington; Patricio T Huerta; Betty Diamond; Bruce T Volpe
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 10.  The neuropathology and pathogenesis of systemic lupus erythematosus.

Authors:  N J Scolding; F G Joseph
Journal:  Neuropathol Appl Neurobiol       Date:  2002-06       Impact factor: 8.090

View more
  13 in total

1.  Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity.

Authors:  Ona Bloom; Kai Fan Cheng; Kai Fen Cheng; Mingzhu He; Angelos Papatheodorou; Bruce T Volpe; Betty Diamond; Yousef Al-Abed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-06       Impact factor: 11.205

Review 2.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 3.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 4.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 5.  Lessons from an anti-DNA autoantibody.

Authors:  Joel Cohen-Solal; Betty Diamond
Journal:  Mol Immunol       Date:  2011-01-07       Impact factor: 4.407

Review 6.  The emerging link between autoimmune disorders and neuropsychiatric disease.

Authors:  Matthew S Kayser; Josep Dalmau
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

Review 7.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

Review 8.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

9.  Neuropsychiatric lupus.

Authors:  Amal Alkhotani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

Review 10.  Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus.

Authors:  Sen Hee Tay; Anselm Mak
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.